Company / Interest Expense
CytomX Therapeutics, Inc. Interest Expense History
FY2016-FY2016 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$1.7M
FY2016
5-year range
-
FY2016-FY2016
Trend
+565.0%
vs FY2015
Sector context
#37 of 44
Health Care
What the data says
CytomX Therapeutics, Inc.'s interest expense of $2M is lower than 84% of companies in the Health Care sector (FY2016).
Based on SEC 10-K filings.
$2M in FY2016.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 16% in Health CareTop 16% of 44This company $1.7M Sector average $291.0M
▼
-99.4% below sector average
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | $1.7M | +565.0% |
As of FY2016 · SEC 10-K · Updated Jul 2, 2026